{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:28Z","timestamp":1790655088849,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1124\/jpet.116.236463","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T03:14:58Z","timestamp":1470107698000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates"],"prefix":"10.1016","volume":"359","author":[{"given":"Steven M.","family":"Weldon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gueneva-Boucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.236463_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/jpet.116.236463_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.116.236463_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1124\/jpet.116.236463_bib4","unstructured":"Balestra M, Burke J, Chen Z, Cogan D, Fader L, Guo X, McKibben B, Marshall D, Richard N, Peter A, et al. (2014) inventors, Boehringer Ingelheim International GmbH, assignee. Aldosterone synthase inhibitors. U.S. patent 20140323468 A1, or US9181272. 2014 Oct 30."},{"key":"10.1124\/jpet.116.236463_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1124\/jpet.116.236463_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.236463_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/jpet.116.236463_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/jpet.116.236463_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/jm00106a038","article-title":"Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease","volume":"34","author":"Browne","year":"1991","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.236463_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1124\/jpet.116.236463_bib11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.116.236463_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsbmb.2015.08.004","article-title":"Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: utility of monkey as a surrogate for human","volume":"154","author":"Cerny","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/jpet.116.236463_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-139-3-200308050-00009","article-title":"Diagnosis of adrenal insufficiency","volume":"139","author":"Dorin","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.116.236463_bib14","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.116.236463_bib15","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1124\/jpet.116.236463_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/jm00062a012","article-title":"Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds","volume":"36","author":"Furet","year":"1993","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.236463_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1124\/jpet.116.236463_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.abb.2010.08.017","article-title":"Multi-step oxidations catalyzed by cytochrome P450 enzymes: processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms","volume":"507","author":"Guengerich","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/jpet.116.236463_bib19","series-title":"L (Gilman A, ed, ed Goodman and Gillman's The Pharmacological Basis of Therapeutics","author":"Hardman","year":"2001"},{"key":"10.1124\/jpet.116.236463_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.116.236463_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.116.236463_bib22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.236463_bib23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.236463_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.116.236463_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.hjh.0000226183.98439.b3","article-title":"Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?","volume":"24","author":"M\u00e9nard","year":"2006","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.116.236463_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"M\u00e9nard","year":"2014","journal-title":"J Transl Med"},{"key":"10.1124\/jpet.116.236463_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/ml400324c","article-title":"Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors","volume":"4","author":"Meredith","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"Suppl 1","key":"10.1124\/jpet.116.236463_bib28","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.116.236463_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MNH.0b013e32834fb25b","article-title":"Extrarenal effects of aldosterone","volume":"21","author":"Nguyen Dinh Cat","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/jpet.116.236463_bib30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/er.2003-0030","article-title":"Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones","volume":"25","author":"Payne","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.116.236463_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/jpet.116.236463_bib32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.116.236463_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/jpet.116.236463_bib34","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1021\/jm901356d","article-title":"Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)","volume":"53","author":"Roumen","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.236463_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10822-007-9128-9","article-title":"Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics","volume":"21","author":"Roumen","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"10.1124\/jpet.116.236463_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem-73-1-99","article-title":"Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor","volume":"73","author":"Santen","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.116.236463_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.116.236463_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1124\/jpet.116.236463_bib39","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"The role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.116.236463_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0024-3205(92)90204-3","article-title":"Adrenal glands of mouse and rat do not synthesize androgens","volume":"50","author":"van Weerden","year":"1992","journal-title":"Life Sci"},{"key":"10.1124\/jpet.116.236463_bib41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1440-1681.2010.05352.x","article-title":"Expanding view of aldosterone action, with an emphasis on rapid action","volume":"37","author":"Vinson","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/jpet.116.236463_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14728222.2013.748750","article-title":"Targeting the mineralocorticoid receptor in cardiovascular disease","volume":"17","author":"Young","year":"2013","journal-title":"Expert Opin Ther Targets"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.236463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:48:46Z","timestamp":1739994526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524194190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0022356524194190"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.236463","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.236463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}